This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis AG.
Prospective comparison of ARNI (angiotensin receptor neprilysin inhibitor) with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure
Reference
McMurray JJV, et al. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart : 21 Dec 2017. Available from: URL: http://doi.org/10.1136/heartjnl-2016-310661
Rights and permissions
About this article
Cite this article
Sacubitril/valsartan good value for money in HF-REF. PharmacoEcon Outcomes News 794, 29 (2018). https://doi.org/10.1007/s40274-018-4627-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4627-6